Radioactive material used in hospitals detected in sewage water RIVM has, for the first time, investigated the possibility of detecting radioactive substances in sewage. This appears to be the case, as RIVM has found iodine-131 and lutetium-177. Hospitals use these substances in the treatment of patients.
Remove ticks quickly, reduce your risk of Lyme disease Ticks are active again, as shown by the increase in tick bite reports on Tekenradar.nl. Quick action is important: the faster you remove a tick after it bites you, the lower your risk of contracting Lyme disease.
More children vaccinated against mumps, measles, rubella and HPV The percentage of newborns participating in the immunisation programme targeting mumps, measles and rubella rose slightly over the past year.
Transfer models for harmful substances in animal feed online now RIVM and Wageningen Food Safety Research have made five feed-food transfer models available to calculate how many harmful substances in animal feed end up in animal-based foods.
Essential to keep a close eye on roll out of 5G The extent to which people are exposed to electromagnetic fields from individual 5G antennas and telephones is below the limits recommended by the European Union.
Control measures against the spread of Legionella from wastewater treatment plants Wastewater treatment plants (WWTPs) may spread Legionella via the air and cause pneumonia if people inhale them.
RIVM welcomes German Federal Centre for Health Education Today RIVM’s Centre for Healthy Living (CGL) welcomes the Bundeszentrale für gesundheitliche Aufklärung.
Scientific background information on rubber granulate now available in English In December 2016, RIVM published in Dutch the results of its research into the health risks of playing sports on synthetic turf pitches with rubber granulate.
Environmentally harmful pharmaceuticals cannot be replaced yet RIVM investigates how the impact of pharmaceutical residues on the environment may be reduced.
Off-label use of medicinal products in the European Union Off-label use of medicinal products in the European Union is common, both in primary and in secondary care.